10x Genomics (TXG) Soars 7.11% on Zacks Upgrade
Mover TrackerMonday, Jun 9, 2025 8:07 pm ET

10x Genomics (TXG) shares surged 7.11% today, marking the second consecutive day of gains, with a total increase of 10.76% over the past two days. The stock price reached its highest level since March 2025, with an intraday gain of 8.07%.
The strategy of buying shares after they reached a recent high and holding for 1 week resulted in a 6.5% gain, but over a 5-year period, it was not enough to recover from an initial 89% loss, indicating the need for more durable strategies.Recent Performance: The stock price of TXG has recently seen a 21% increase over the past month, and a 6.5% increase over the past week. This short-term momentum can be enticing for investors looking for a quick gain.
Long-Term Performance: However, when considering the past 5 years, the stock's performance was lackluster. The share price has plummeted by 89% since then, and the current price is still below the initial level, despite the recent recovery.
Annual Performance: Over the past 5 years, TXG grew its revenue at an annual rate of 18%, which is robust for a company without profits. This growth in revenue might not have been sufficient to boost the share price, possibly due to market sentiment or overvaluation.
Insider Activity: There has been significant insider buying in the last quarter, which could be a positive signal. However, the focus on short-term performance and the lack of profitability in the company are red flags that investors should consider.
Market Sentiment: The short interest in TXG has decreased, which can be a bullish indicator as it suggests that traders are less bearish on the stock. However, peer comparison shows that TXG has more short interest than most of its peers, which could persist due to market skepticism.
Analyst Forecasts: The average analyst one-year target price for TXG is $12.68, with a high estimate of $18.00 and a low estimate of $6.50. This suggests that analysts see potential for growth from the current price level, but the downside risk is still significant.
Fundamental Valuation: The GF Value for TXG in one year is estimated to be $38.89, which suggests a significant upside from the current price of $9.11. This indicates that based on historical multiples and growth estimates, the stock could be undervalued.
In conclusion, while the recent uptick in the stock price is positive, it may not be enough to sustain a long-term recovery. Investors should carefully evaluate the company's fundamentals, market position, and growth prospects before making investment decisions. The performance of holding TXG shares after a recent high for 1 week, despite the 5-year decline, highlights the importance of considering long-term strategies and not 。
10x Genomics has recently been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This positive rating change is likely to drive investor interest and potentially boost the stock price.
Despite the recent price surge, UBS analyst John Sourbeer lowered the price target for
from $14.00 to $12.00. This adjustment may influence investor expectations and stock valuation, as analysts' price targets often serve as benchmarks for market sentiment.
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
Comments
No comments yet